Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 644.11

+2.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (128)	7/27/1997 5:44:00 PM
From: Miljenko Zuanic	Read Replies (1) of 3557

Hi Rick: Thanks for update from Angiogenesis Con. at SF. Did Dr. Yancopoulos disclose any preclinical data on Angiopoetins (proteins ligand) as positive and negative regulator of the angiogenic TIE receptors. Can we expect IND in near future (to me great interest is on positive regulator-promotion of the blood shells grow)? Dr. Yancopoulos will have clinical trials (probably preclinical) data presentation at Angiogenesis Antagonist Conference at Hamilton HM, Bermuda (Oct. 19-20) on TIE Receptor Antagonists. I checked for NT-3. It seams that results will be available somewhere at the year end. Something else triggered Thursday afternoon race. Maybe Glaxo collaboration or small intrathecal BDNF trials! Will know this week. Also, this is not of the big importance. Time is working for REGN and its SH. By any chance, did you attended any presentation at Tumor Suppressors and Oncogenes Conf. at SF? My interest is on Dr. Monia (from Isis Pharm.) lecture on Ras/Raf antisense development and clinical data. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next